In a land­mark OK, FDA green-lights Bris­tol-My­er­s' Op­di­vo for a niche group of metasta­t­ic lung can­cer pa­tients

Bris­tol-My­ers Squibb $BMY may have lost the long-run­ning bat­tle with Mer­ck $MRK for lead­ing the in­dus­try on over­all check­point rev­enue, but they are still fight­ing for every edge they can get look­ing for a come­back to the top spot.

To­day the bio­phar­ma com­pa­ny an­nounced that the FDA has ap­proved its block­buster PD-1 drug Op­di­vo for metasta­t­ic small cell lung can­cer pa­tients who had failed chemo and one oth­er ther­a­py. The OK is based on SCLC co­hort da­ta that Bris­tol-My­ers as­sem­bled in its Check­Mate-032 Phase I/II tri­al — with a 12% re­sponse rate that in­clud­ed 1 com­plete and 12 par­tial re­spons­es. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER